# EDGAR Filing Document

**Accession Number:** 0000791908
**File Stem:** 0001193125-26-009726
**Filing Date:** 2026-1
**Character Count:** 12055
**Document Hash:** b16d6d81e447f7fd16aa3353dcde40c8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-009726.hdr.sgml**: 20260112

**ACCESSION NUMBER**: 0001193125-26-009726

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 24

**CONFORMED PERIOD OF REPORT**: 20260112

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260112

**DATE AS OF CHANGE**: 20260112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** XOMA Royalty Corp
- **CENTRAL INDEX KEY:** 0000791908
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 522154066
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39801
- **FILM NUMBER:** 26524618

**BUSINESS ADDRESS:**
- **STREET 1:** 2200 POWELL STREET
- **STREET 2:** SUITE 310
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608
- **BUSINESS PHONE:** 510-204-7239

**MAIL ADDRESS:**
- **STREET 1:** 2200 POWELL STREET
- **STREET 2:** SUITE 310
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** XOMA Corp
- **DATE OF NAME CHANGE:** 20120119

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** XOMA LTD /DE/
- **DATE OF NAME CHANGE:** 19990107

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** XOMA CORP /DE/
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of Earliest Event Reported): January 12, 2026

## XOMA ROYALTY CORPORATION

#### (Exact Name of Registrant as Specified in Charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **001-39801** | **52-2154066** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer<br>Identification Number)** |

---

#### 2200 Powell Street, Suite 310

#### Emeryville, California 94608

#### (Address of Principal Executive Offices)
(510) 204-7200

#### (Registrant's telephone number, including area code)

#### (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| Common Stock, $0.0075 par value | XOMA | The Nasdaq Global Market |
| 8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share | XOMAP | The Nasdaq Global Market |
| Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share) | XOMAO | The Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 7.01.** | **Regulation FD Disclosure.**  |

---

On January 12, 2026, XOMA Royalty Corporation, a Nevada corporation (the "Company"), made available an updated corporate presentation, which is attached to this Current Report on Form 8-K as Exhibit 99.1.

The information contained in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.**  |

---

*(d) Exhibits.* 

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| 99.1 | [Corporate Presentation, dated January 12, 2026.](d30416dex991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **XOMA ROYALTY CORPORATION** | **XOMA ROYALTY CORPORATION** |
| Date: January 12, 2026 | By: | /s/ Owen Hughes |
|  | **Name:** | Owen Hughes |
|  | **Title:** | Chief Executive Officer |

---

## Exhibit 99.1

![](g30416ex99_1p1g1.jpg)

Exhibit 99.1 CORPORATE PRESENTATION THE ROYALTY AGGREGATOR NASDAQ COMMON: XOMA FOR BIOTECH NASDAQ PERPETUAL PREFERRED SHARES: XOMAP, XOMAO COMPANIES JANUARY 2026

------

![](g30416ex99_1p2g1.jpg)

DISCLAIMERS Certain statements in this presentation are forward-looking statements XOMA Royalty's views only as of the date of this presentation and within the meaning of Section 27A of the Securities Act of 1933 and should not be relied upon as representing its views as of any Section 21E of the Securities Exchange Act of 1934, including subsequent date. XOMA Royalty disclaims any obligation to update any statements regarding: future potential monetization opportunities, forward-looking statement, except as required by law. active transactions with significant financial implications, collaborations poised for significant financial contribution, the ability of our partners NOTE: All references to "portfolio" in this presentation are to milestone and their licensees to successfully develop their pipeline programs, the and/or royalty rights associated with a basket of drug products in productivity of acquired assets, our revenue and cashflow forecasts, development. All references to "assets" in this presentation are to upcoming internal milestones and value catalysts, our future cash milestone and/or royalty rights associated with individual drug product needs, our strategy for value creation, and other statements that relate candidates in development. References to royalties or royalty rates to future periods. These statements are not guarantees of future contained herein refer to future potential payment streams regardless performance and undue reliance should not be placed on them. They of whether or not they are technically defined as royalties in the are based on assumptions that may not prove accurate, and actual underlying contractual agreement; further, any rates referenced herein results could differ materially from those anticipated due to certain risks are subject to potential future contractual adjustments. inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. Potential risks to XOMA Royalty meeting these expectations are described in more detail in XOMA Royalty's most recent filings on Form 10-K and Form 10-Q. Consider such risks carefully when considering XOMA Royalty's prospects. Any forward-looking statements represent 2

------

![](g30416ex99_1p3g1.jpg)

XOMA ROYALTY – WHAT WE DO Royalties Science Milestones Structuring The Biotech Royalty Aggregator 3

------

![](g30416ex99_1p4g1.jpg)

XOMA ROYALTY SNAPSHOT: Current Capitalization $(1) 27.21 / SHARE SHARES (FULLY DILUTED 18.6M TREASURY METHOD) $~$ MARKET CAP (FULLY DILUTED) 506M 598M $65M PERPETUAL PREFERREDS ENTERPRISE VALUE $112M ROYALTY BACKED LOAN $(2) 85M CASH (1) Share price as of market close 01/07/2026 (2) Cash available to XOMA Royalty as of 09/30/2025 (Reported $130.6M including $85.4M of restricted 4 4 cash. $39.9M of restricted cash was temporarily reserved to fund the Mural Oncology acquisition.)

------

![](g30416ex99_1p5g1.jpg)

XOMA ROYALTY IS DIFFERENTIATED Capital per transaction $200M+ Royalty Pharma $200M – $100M DRI Healthcare Trust FOCUSED ON $ Ligand HCRx 100M – EARLY- to MID-STAGE $25M CLINICAL ASSETS $< 25M P R E C L I N I C A L PHASE 1 PHASE 2 PHASE 3 AP P R O VAL CO M M E R CI A L 5

------

![](g30416ex99_1p6g1.jpg)

XOMA ROYALTY'S BUSINESS MODEL: Path to Sustained THE COMPOUNDING Profitability EFFECT GROWING # of ROYALTIES CASH RECEIPTS ↑ LOW EXPENSES LOW SHARE COUNT INFLECTION POINT HIGH EPS LOW EXPENSES SIGNIFICANT SHARE PRICE APPRECIATION 2023 future 6

------

![](g30416ex99_1p7g1.jpg)

XOMA ROYALTY'S BUSINESS MODEL DIFFERENTIATION SHOULD ENHANCE VALUE CREATION DCF VALUE + Visibility into future PIPELINE royalty portfolio DCF differentiates VALUE XOMA ROYALTY from majority of royalty competitors TIME 7 VALUE

------

![](g30416ex99_1p8g1.jpg)

2025 YEAR IN REVIEW: REPUTATION INFLECTION The TRINITY: Assets / Tax Benefits / Cash A P R 2025 J U L 2025 J A N 2025 M A Y 2025 1 O U T L IC E N S IN G R O Y ALT Y A C Q U IS IT IO N R O Y ALT Y + ADDITIONAL D-Fi Royalty, Warrants Sale of All Pipeline Assets Mezagitamab Royalty Cash +24 PRV ASSETS N A S DA Q : K N T E N A S DA Q : E P I X P R I VAT E N A S DA Q (S W) : B I N V A U G 2025 A U G 2025 A U G 2025 A U G 2025 A C Q U IS IT IO N A C Q U IS IT IO N A C Q U IS IT IO N A C Q U IS IT IO N SEC 174 $2 SEC 174 Benefits SEC 174 Benefits SEC 174 Benefits ~ 525M BENEFITS N A S DA Q : M U R A N A S DA Q : L V T X N A S DA Q : T S B X N A S DA Q : H L V X N O V 2 025 D E C 2025 D E C 2025 NON- 1 R O Y ALT Y X -Δ A C Q U IS IT IO N A C Q U IS IT IO N ~$ DILUTIVE ctLNP Royalty Share Agreement 13M Platform CAPITAL N Y S E : T A K N A S DA Q : R P R X N A S DA Q : G B I O 1. XOMA Royalty served as Structuring Agent and financing source to XenoTherapeutics, Inc. 2. Value includes estimated Section 174 tax deductions related to unamortized R&E from announced transactions where closing is pending. 8 Announced – Closing Pending

------

![](g30416ex99_1p9g1.jpg)

BUILDING THE LONG-TERM XOMA ROYALTY BUSINESS >100 Assets seralutinib (PAH/PH-ILD) (1L pLGG) ersodetug (THI) mezagitamab (ITP/IgAN) volixibat (PBC/PSC) (1) $ osavampator (MDD) > 140M OHB-607 (BPD) milestones received since 2017 rilvegostomig (cancer) UNDISCLOSED Anti-TL1A (UC/Crohn's) $(2) > 2B ficlatuzumab (HNSCC) in future potential cetrelimab (cancer) milestones ovaprene (NH Contraception) D-Fi (DEB) sildenafil cream (FSAD) MILESTONES EARLY-STAGE PIPELINE REGISTRATIONAL / PHASE 2b & 3 COMMERCIAL ROYALTIES 1. Pending the Close of the acquisition of Generation Bio. 2. Pending the Close of the acquisition of Repare Therapeutics by XenoTherapeutics, Inc. 9

------

![](g30416ex99_1p10g1.jpg)

+ B U S I N E S S D E V E L O P M E N T KEY PORTFOLIO EVENTS ANTICIPATED IN 2026 R E G U L A T O R Y C O M M E R C I A L S A L E S R A M P S E M A D E C I S I O N R E G U L A T O R Y G U I D A N C E E R S O D E T U G (R E Z O L U T E) R E C - 4881 (R E C U R S I O N P H A R M A) D A T A A N N O U N C E M E N T S PHASE 3 PHASE 3 PHASE 2 P R O D U C T L A U N C H S E R A L U T I N I B R I L V E G O S T O M I G E R S O D E T U G P U L M O N A R Y A R T E R I A L H Y P E R I N S U L I N I S M G A S T R I C / L U N G H Y P E R T E N S I O N (P A H) (T H I) C A N C E R 10